ZK 230211 in Postmenopausal Woman With Metastatic Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Metastatic Breast Cancer
Interventions: DRUG: Lonaprisan (ZK 230211, BAY86-5044)|DRUG: Lonaprisan (ZK 230211, BAY86-5044)
Sponsor: Bayer